Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Completed · Phase 1/Phase 2

Conditions studied: AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma

In brief

This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.

Key facts

Study ID

NCT01057121

Run by

National Cancer Institute (NCI)

People needed

38

Starts

2010-08-27

Expected to finish

2014-08-04

Last updated by the study team

2022-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy-proven KS involving skin with or without visceral involvement either newly diagnosed or refractory to or intolerant of one or more prior therapies
• Patients must have cutaneous lesion(s) amenable to four 3 mm tumor biopsies during the study (either 4 separate lesions measuring > 4 mm each OR 2 separate lesions measuring > 8 mm each) and at least five additional lesions measurable for assessment with no improvement over the past month
• Serologic documentation of HIV infection by any of the Food and Drug Administration (FDA)-approved tests
• Karnofsky performance status >= 60%
• Hemoglobin >= 8 g/dL
• Absolute neutrophil count (ANC) >= 1,000 cells/mm\^3
• Platelet count >= 100,000/mm\^3
• Calculated (method of Cockcroft-Gault) creatinine clearance (CrCl) >= 60 mL/min in the Phase I and CrCl >= 30 mL/min in the Phase II (creatinine clearance may also be obtained by the 24-hour collection method at the investigator's discretion)
• Total bilirubin should be =< 1.5x upper limit of normal (ULN); if, however, the elevated bilirubin is felt to be secondary to Atazanavir therapy, patients will be allowed to enroll on protocol if the total bilirubin is =< 3.5 mg/dL provided that the direct bilirubin is normal
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3x ULN
• Life expectancy >= 3 months
• Ability and willingness to give informed consent
• Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours prior to starting Cycle 1 of lenalidomide; further, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during receipt of lenalidomide, and 28 days after discontinuation of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
• Patients must, in the opinion of the investigator, be capable of complying with the protocol
• All patients must be on antiretroviral therapy for HIV infection with CD4 count > 50/mm\^3 and viral load < 2,000 copies/mL; patients must be on a stable regimen for at least 12 weeks prior to study entry; patients may receive any FDA approved antiretroviral therapy except for zidovudine
• There should be no evidence for improvement in KS in the 3 months prior to study entry, unless there is evidence for progression of KS in the 4 weeks immediately prior to study entry
• If antiretroviral regimen contains zidovudine and viral load is suppressed (as measured by HIV viral load =< 200/mL), then antiretroviral therapy must be adjusted to a less toxic therapy not containing zidovudine and enrollment may proceed without waiting 12 weeks; if on zidovudine-containing therapy and viral load is not suppressed (as measured by HIV viral load >= 200/mL), then antiretroviral therapy must be adjusted to a less toxic regimen allowing for optimal viral suppression and must demonstrate stability for at least 12 weeks prior to study entry
• Patients with any history of pulmonary embolism (PE) or deep venous thrombosis (DVT) or predisposing clotting risk factors must be on anticoagulation at therapeutic dosing

You may not qualify if…

• Concurrent, acute, active opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment
• Patients for whom front-line cytotoxic therapy is indicated (i.e. symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status)
• Concurrent neoplasia requiring cytotoxic therapy
• Acute treatment for an infection (other than oral thrush or genital herpes) or other serious medical illness within 14 days of study entry
• Anti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local therapy including topical 5-FU, biological therapy, or investigational therapy) within four weeks of study entry
• Any steroid treatment except for that required for replacement therapy in adrenal insufficiency or inhaled steroids for the treatment of asthma
• Patient is =< 2 years free of another primary malignancy; exceptions include the following:
• Basal cell skin cancer
• Cervical carcinoma in situ
• Anal carcinoma in situ
• Previous local therapy of any KS-indicator lesion unless the lesion has clearly progressed since treatment; any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesion
• Use of any investigational drug or treatment within 4 weeks prior to enrollment
• Physical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity or non-compliance
• Female patients who are pregnant or breast-feeding
• Patients with a history of DVT or PE within 1 year
• Patients requiring blood transfusions to maintain Hgb eligibility
• Patients on erythropoietin-stimulating agents (ESA) unless also on therapeutic anticoagulation
• Patients with CD4 < 50 mm\^3 and/or viral load > 2,000 copies/mL
• Patients on estrogen therapy unless also on therapeutic anticoagulation

Where it is running

• UCLA Center for Clinical AIDS Research and Education — Los Angeles, California, United States
• University of California San Diego — San Diego, California, United States
• San Francisco General Hospital — San Francisco, California, United States
• University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida, United States
• Cancer Center of Hawaii-Hawaii AIDS Clinical Research Program — Honolulu, Hawaii, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Pennsylvania Oncology Hematology Associates — Philadelphia, Pennsylvania, United States
• Thomas Street Clinic — Houston, Texas, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• Harborview Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.